Related Experiment Videos
Atherosclerosis and diabetes: the RAGE connection.
1Department of Surgery, College of Physicians & Surgeons of Columbia University, 630 West 168th Street, New York, New York 10032, USA.
Current Atherosclerosis Reports
|December 21, 2000
Summary
Diabetes complications, like atherosclerosis, significantly impact patient quality of life. Targeting the receptor for advanced glycation endproducts (RAGE) may offer a new therapeutic strategy for diabetic macrovascular disease.
Area of Science:
- Biomedical Science
- Endocrinology
- Cardiovascular Research
Background:
- Diabetes mellitus is a metabolic disorder with progressive, systemic complications.
- Accelerated atherosclerosis is a leading cause of morbidity and mortality in diabetic patients.
- Understanding the mechanisms of diabetic atherosclerosis is crucial for improving patient outcomes.
Purpose of the Study:
- To review the role of the receptor for advanced glycation endproducts (RAGE) and its ligands in diabetic atherosclerosis.
- To explore RAGE as a potential therapeutic target for macrovascular complications in diabetes.
Main Methods:
- Literature review of studies investigating RAGE, advanced glycation endproducts (AGEs), and S100/calgranulins in diabetes.
- Analysis of the role of these molecules in the pathogenesis of atherosclerosis.
Main Results:
- RAGE and its ligands (AGEs, S100/calgranulins) are implicated in the development of atherosclerosis in diabetes.
- The RAGE pathway contributes to the pathogenesis of macrovascular disease in diabetic individuals.
Conclusions:
- The receptor for advanced glycation endproducts (RAGE) is a key player in diabetic atherosclerosis.
- Targeting RAGE presents a promising therapeutic avenue for managing macrovascular disease in diabetes mellitus.